In recent years, immunotherapy represented by PD‐1/PD‐L1 inhibitors has changed the treatment mode in advanced lung cancer, and has become the standard treatment option for NSCLC.19, 29, 30. This evidence concerns the gene CD274 and non-small cell lung carcinoma.